IL-12 p70 / IL12A (Protein | Antibody | cDNA Clone | ELISA Kit)

All IL-12 p70 / IL12A reagents are produced in house and quality controlled, including 5 IL-12 p70 / IL12A Antibody, 65 IL-12 p70 / IL12A Gene, 3 IL-12 p70 / IL12A Lysate, 3 IL-12 p70 / IL12A Protein, 3 IL-12 p70 / IL12A qPCR. All IL-12 p70 / IL12A reagents are ready to use.

More Product Popular With Customers

IL-12 p70 / IL12A Background

Interleukin-12 subunit alpha (IL12A/IL-12p35) is also known as Cytotoxic lymphocyte maturation factor 35 kDa subunit, cytotoxic lymphocyte maturation factor 1, p35, NK cell stimulatory factor chain 1, and interleukin-12 alpha chain. IL12A/IL-12p35 is a subunit of a cytokine that acts on T and natural killer cells, and has a broad array of biological activities. The cytokine is a disulfide-linked heterodimer composed of the 35-kD subunit encoded by this gene, and a 4-kD subunit that is a member of the cytokine receptor family. IL12A/IL-12p35 is required for the T-cell-independent induction of IFN-gamma, and is important for the differentiation of both Th1 and Th2 cells. The responses of lymphocytes to this cytokine are mediated by the activator of transcription protein STAT4. Nitric oxide synthase 2A (NOS2A/NOS2) is found to be required for the signaling process of this cytokine in innate immunity. In clinical, IL-12 remains a very promising immunotherapeutic agent because recent cancer vaccination studies in animal models and humans have demonstrated its powerful adjuvant properties. The immune modulating characteristics of IL-12 considered responsible for the adjuvant effects, as well as the results of animal and human cancer vaccination studies with IL-12 applied as an adjuvant. IL12A/IL-12p35 indicates a cytokine which is important in the development of prostate cancer.

IL-12 p70 / IL12A References

  • Sattler HP, et al. (2000) Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate. 45(3): 207-15.
  • Lamont AG, et al. (1996) IL-12: a key cytokine in immune regulation. Immunol Today. 17(5): 214-7.
  • Portielje JE, et al. (2003) IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother. 52(3): 133-44.
彩票大奖得主捐赠 股票推荐·天牛宝名气 股票推荐软件手机板 pmi 上证指数 湖南体彩幸运赛车走势 内蒙古期货股票配资 好运快三下载 排列5预测最准十专家 道氏技术股票趋势 内蒙古11选五任选走势图 辽宁快乐12推荐号怎么查